medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Title: COVID-19 vaccine effectiveness during a prison outbreak when the Omicron was the dominant circulating variant— Zambia, December 2021

Authors: John Simwanza[1,2]; Jonas Z. Hines[3]; Danny Sinyange[1,2]; Nyambe Sinyange[4]; Chilufya Mulenga[1,4]; Sarah Hanyinza[4]; Patrick Sakubita[4], Nelia Langa[4]; Haggai Nowa[5]; Priscilla Gardner[6]; Ngonda Saasa[7]; Gabriel Chipeta[6]; James Simpungwe[3]; Warren Malambo[3]; Busiku Hamainza[2]; Nathan Kapata[4]; Muzala Kapina[4]; Kunda Musonda[4]; Mazyanga Liwewe[4]; Consity Mwale[6]; Sombo Fwoloshi[9]; Lloyd B. Mulenga[9]; Simon Agolory[3]; Victor Mukonka[4]; Roma Chilengi[4,10];

Affiliations:

[1]Zambia Field Epidemiology Training Programme, Lusaka, Zambia

[2]National Malaria Elimination Centre, Lusaka, Zambia

[3]Centers for Disease Control and Prevention, Lusaka, Zambia

[4]Zambia National Public Health Institute, Lusaka, Zambia

[5]Zambia Prison Services, Lusaka, Zambia

[6]Lusaka District Health Office, Lusaka, Zambia

[7]University of Zambia Veterinary Medicine Laboratory School, Lusaka, Zambia

[8]Lusaka Province Health Office, Lusaka, Zambia

[9]Ministry of Health, Lusaka, Zambia

[10]Republic of Zambia State House, Lusaka, Zambia

Keywords: COVID-19 vaccines, vaccine efficacy; SARS-CoV-2 variants, prisons, prisoners, Zambia, Africa

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Abstract: During a COVID-19 outbreak in a prison in Zambia from 14th to 19th December 2021, a case control study was done to measure vaccine effectiveness (VE) against infection and symptomatic infection, when the Omicron variant was the dominant circulating variant. Among 382 participants, 74.1% were fully vaccinated and the median time since full vaccination was 54 days. There were no hospitalizations or deaths. COVID-19 VE against any SARS-CoV-2 infection was 64.8% and VE against symptomatic SARS-CoV-2 infection was 72.9%. COVID-19 vaccination helped protect incarcerated persons against SARS-CoV-2 infection during an outbreak while Omicron was the dominant variant in Zambia.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Introduction

COVID-19 continues to ravage the globe as new SARS-CoV-2 variants emerge and cause new waves of infections. The highly transmissible Omicron variant emerged in late 2021, rapidly spreading to many countries and leading to record-breaking case counts globally. In early December 2021, Zambia recorded a rapid rise in confirmed COVID-19 cases, coinciding with confirmation of the Omicron variant in the country. Zambia recorded a daily average of 1,422 confirmed COVID-19 cases in December 2021, compared to an average 15 cases daily the previous month, in November 2021. From December 4th to 24th, 2021, all sequenced specimens in Zambia were of the Omicron variant (1).

Congregate living settings, including prisons, are at high risk for COVID-19 outbreaks (2). Congested living conditions make physical distancing and avoidance of crowds challenging in many prison settings. Although difficult to enforce, use of face masks in high SARS-CoV-2 transmission risk settings can limit the rapid spread of infection (3).

On December 14th, 2021, after not recording any COVID-19 cases for months, a local prison in Lusaka noted an increase in the number of residents with respiratory symptoms, 19 of whom tested positive for COVID-19 with rapid diagnostic tests (RDTs). The prison notified the Lusaka District Health Office on the same day and an outbreak investigation was initiated. Mitigation measures were reinforced, including mask distribution and mandatory masking, cohorting persons testing positive and provision of hand hygiene stations throughout the prison. Of 767 persons incarcerated at the facility during the outbreak, 241 (31.4%) tested positive for COVID-19 from December 14th to 19th, 2021.

COVID-19 vaccines have shown remarkable effectiveness, particularly for reducing COVID-19 severity (4). COVID-19 vaccine effectiveness (VE) against the Omicron variant is lower than against other variants (5,6), although data from the African continent are limited (7–9). Correctional services in Zambia achieved high COVID-19 vaccine coverage among incarcerated persons prior to the Omicron variant wave through onsite vaccination clinics

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

and enhanced COVID-19 screening and testing with encouragement of vaccination for those testing negative. Of the incarcerated persons at this local prison, 619 (80.7%) were vaccinated when the outbreak occurred (compared to 12.6% of the eligible general population in Zambian at the time). We measured VE among incarcerated persons during this outbreak in Zambia.

Methods

A case-control study of SARS-CoV-2 infection and symptomatic infection by vaccination status was conducted among persons incarcerated at the prison facility during the outbreak from 15th to 20th December 2021. The facility is in Lusaka, the national capital of Zambia, and houses men aged ≥13 years awaiting court cases or transfer to other prisons after sentencing. The prison has five cells built to house 92 persons, although at the outbreak onset 767 persons were incarcerated (i.e., > 800% beyond capacity).

During the outbreak, all incarcerated persons were tested for COVID-19 using Panbio COVID-19 Ag rapid test (Abbott Rapid Diagnostics Jena GmbH, Germany) from December 14th to 19th, 2021. Cases and controls were incarcerated persons testing COVID-19 positive and negative, respectively. Participants were recruited into the study between December 20th to 24th, 2021 by reviewing the outbreak line list maintained by the prison health team and district health office, attempting to frequency match controls by cases' cell assignment. Verbal consent was obtained from the participants and for minors aged 13–17 years. Consent was obtained from the prison warden as per Zambia Correctional Services policy. This study was approved by the ERES Ethics review board and National Health Research Authority. The activity was reviewed by US Centers for Disease Control and Prevention and was conducted consistent with applicable Federal law and CDC policy.

A standardized questionnaire that included information on demographics and medical history, including COVID-19 vaccination and test results was administered by trained

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

interviewers. Self-reported COVID-19 test results were confirmed with the line list where the RDT results were recorded. Vaccination status was cross-referenced with the national registry.

Full vaccination was defined as having received the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days before COVID-19 testing. Partial vaccination was defined as having received the 1st dose of a two-dose vaccine ≥14 days before COVID-19 testing but not the 2nd dose yet or receiving the 2nd dose ≤13 days before testing. Persons who were partially vaccinated or indeterminate status (i.e., received their 1st dose of the One dose vaccine 0-13 days before testing, or had an unknown type of COVID-19 vaccine) were excluded from analyses. Multivariable logistic regression was used to calculate the odds of SARS-CoV-2 infection and symptomatic infection, adjusting for age, number of comorbidities, jail cell, and self-reported mask use. VE was calculated as 1 minus the adjusted odds ratio times 100. To reduce the risk of misclassification bias related to false negative RDT test results, we conducted a sensitivity analysis excluding symptomatic controls.

Results

In total, 385 (50.2%) of the 767 incarcerated persons present during the outbreak were reached for interview and 382 (49.8%) consented to being enrolled in the study. All were males, with a median age of 28 years (interquartile range [IQR]: 21-36 years) (Table 1). Overall, 84 (22.0%) had at least one comorbidity, with HIV being most common (n = 40, 10.5%). Only 16 (4.1%) reported having had COVID-19 previously.

Overall, 294 (77.0%) participants received ≥1 COVID-19 vaccine dose; of these 283 (96.3%) were fully vaccinated, 1 (0.3%) partially vaccinated and 10 (3.4%) indeterminate. Among fully vaccinated participants, 253 (89.4%) received the one-dose Janssen vaccine and 30 (10.6%) received the two-dose AstraZeneca vaccines. None had received an additional

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

('booster') vaccine dose. The median time since receipt of a full primary vaccine series was 54 days (IQR: 28-85 days).

There were 180 (47.1%) COVID-19 positive incarcerated persons (i.e., cases) and 202 (52.9%) COVID-19 negative persons (i.e., controls). Among positive cases, 117 (65.0%) were in fully vaccinated persons (i.e., breakthrough infections). Of the 16 (4.1%) persons reporting prior confirmed COVID-19, 5 (29.4%) were positive during the outbreak (i.e., reinfections).

Overall, 104 (27.2%) persons reported any COVID-19 symptoms, with a greater proportion among cases (45.6% vs. 10.9%; $p < 0.01$, chi-square test). The most common symptoms among COVID-19 cases were cough (37.8%), rhinorrhoea (20.6%), headache (17.2%), and myalgias (12.8%) (Table 1). Eighty-nine (49.4%) of the 180 participants with cases sought medical care at the prison clinic, and none (0%) were admitted or died. Cases were more likely to have sought health care. There were no differences among the cases and controls in terms of age, number of comorbidities, prior Covid-19, or mask use.

Cases were less likely to be fully vaccinated than controls (66.9% versus 84.7%; $p<0.01$, chi-square test) (Table 2). VE against SARS-CoV-2 infection was 64.8% (95% confidence interval [CI]: 36.1-81.0%) and VE against symptomatic SARS-CoV2 infection was 72.9% (95% CI: 42.0-87.5%). The median time to vaccination was less than two months and the VE was higher for those vaccinated within the past 60 days compared to >60 days before COVID-19 testing, although the confidence intervals overlapped (VE for SARS-CoV-2 infection: 74.6% [95% CI: 50.3-87.4%] vs. 54.2% [95% CI: 6.9-77.9%], respectively). VE of Janssen vaccine against SARS-CoV-2 infection was 63.6% (95% CI: 33.6-80.5%) and against symptomatic infection was 73.0% (95% CI: 41.6-87.7%). VE of AstraZeneca against SARS-CoV-2 infection was 89.4% (95% CI: 59.5-97.8%) and against symptomatic infection was 83.7% (95% CI: 60.8-93.6%). The sensitivity analysis excluding symptomatic controls did not meaningfully change the VE estimates (VE against SARS-CoV-2 infection was

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

64.1% [95% CI: 35.8-80.2%] and VE against symptomatic SARS-CoV2 infection was 73.4% [95% CI: 44.6-87.4%]). Forty persons (10.5%) in the analysis reported being HIV positive, among who 83.3% of unvaccinated PLHIV tested SARS-CoV-2 positive compared to 50.0% of fully vaccinated PLHIV (p = 0.20, chi-square test). Among PLHIV, VE against SARS-CoV-2 infection was 82.2% (95% CI: -107-99.4%).

Discussion

During a prison COVID-19 outbreak in Zambia, COVID-19 vaccination protected against SARS-CoV-2 infection and symptomatic illness while Omicron was the dominant strain in the country (1). These findings provide important evidence that might help increase COVID-19 vaccination in Zambia, where many more Zambians need to be vaccinated to reach the African Union targets adopted by the country (10).

The SARS-CoV-2 Omicron variant contains numerous mutations to the spike protein which may lead to immune evasion. VE estimates reported here are lower compared to prior strains (11,12), and the high proportion of breakthrough infections in this outbreak supports in theory the possibility of immune evading capability of Omicron. In this study, VE was higher for symptomatic illness than any infection; VE for severe illness could not be accessed because no persons were hospitalized or died during this outbreak although other studies have demonstrated durability against this important outcome (13). Similarly, VE of a booster dose could not be assessed because Zambia did not begin offering a booster dose until January 2022. The relatively short time since vaccination might explain the relatively higher effectiveness findings against Omicron (6,14,15), although there was a suggestion of waning immunity when comparing the VE point estimates of participants fully vaccinated over two months before the outbreak with those vaccinated within the past two months. Our findings are encouraging considering alarm raised early in the Omicron wave about the

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

vaccines widely available in Africa being ineffective against reducing SARS-CoV-2 transmission (16).

Notably, symptomology was mild among participants, which is consistent with reports from other countries that are experiencing Omicron surges (9,17). Animal evidence suggests this might be related to tropism of Omicron for upper respiratory epithelium relative to the lower respiratory tract (18). This finding might also reflect the relatively younger age of persons in this outbreak. The role of pre-existing immunity in Zambia from natural infection remains uncertain and serosurveys would be useful to understand to what proportion of people in Zambia have been infected with SARS-CoV-2.

This study had several limitations. All cases were confirmed with RDTs, which have lower sensitivity than PCR tests (19). Additionally, beyond initial test results, serial testing was not available meaning some controls might have been in their incubation period at the time of testing and therefore misclassified. Omicron was not confirmed by genomic sequencing in this outbreak, so the outbreak could have been from another strain; however, Omicron was already dominant in Zambia before this outbreak occurred (20). Lastly, although few participants reported a prior confirmed SARS-CoV-2 infection, the actual number might be much higher considering only a small proportion of cases are confirmed in Zambia (21).

Rapid investigation of an outbreak in a closed setting demonstrated VE of COVID-19 vaccines against Omicron infection in Zambia. COVID-19 vaccination remains a critical tool in decreasing SARS-CoV-2 transmission and severity especially when coupled with a layered prevention including well-fitting facemask use, hand hygiene, limiting large gatherings, and adequate ventilation and/or outdoor gatherings. Continuing to rapidly scale COVID-19 vaccination to all eligible persons in Zambia can help prevent SARS-CoV-2 transmission and symptomatic COVID-19.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Attribution of Support: This work has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) and the CDC Emergency Response to the COVID-19 pandemic.

Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies. Use of trade names is for identification only and does not imply endorsement by the funding agencies.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

References

1. GISAID - EpiCov [Internet]. [cited 2022 Feb 18]. Available from: https://www.epicov.org/epi3/frontend#220b8c

2. Hagan LM, McCormick DW, Lee C, Sleweon S, Nicolae L, Dixon T, et al. Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep;70(38):1349–54.

3. Centers for Disease Control and Prevention (CDC). Science Brief: Community Use of Masks to Control the Spread of SARS-CoV-2 [Internet]. December 6, 2021. [cited 2022 Mar 5]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html

4. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022 Jan;114:252–60.

5. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv [Internet]. 2021 Dec;2021.12.14.21267615. Available from: https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1.abstract

6. Thompson MG, Natarajan K, Irving SA. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–. Morb Mortal Wkly Rep [Internet]. ePub: 21 J. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcitation

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

7. Grey GE, Collie S, Garrett N, Goga A, Champion J, Zylstra M, et al. Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study. medRxiv [Internet]. Available from: https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1

8. Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet (London, England). 2022 Mar;399(10330):1141–53.

9. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. Vol. 386, The New England journal of medicine. 2022. p. 494–6.

10. World Health Organization (WHO). Leaders Make Urgent Call To Accelerate Vaccination Globally And In Africa [Internet]. Geneva, Switzerland; Available from: https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-vaccination-globally-and-in-africa

11. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep;70(38):1337–43.

12. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022 Jan;

13. Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Morb Mortal Wkly Rep. 2022 Mar;71(12):459–65.

14. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr;386(16):1532–46.

15. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb;71(7):255–63.

16. Nolen S. Most of the World's Vaccines Likely Won't Prevent Infection From Omicron. The New York Times [Internet]. Available from: https://www.nytimes.com/2021/12/19/health/omicron-vaccines-efficacy.html

17. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA. 2021 Dec;

18. Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, et al. SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. bioRxiv. 2021 Dec;2021.12.26.474085.

19. Akingba OL, Sprong K, Marais G, Hardie DR. Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant in the Eastern Cape, South Africa. J Clin Virol Plus [Internet]. 2021;1(1–2):100013. Available from: https://doi.org/10.1016/j.jcvp.2021.100013

20. Mwenda-Chimfwembe M, Saasa N, Bridges D. Genomic epidemiology of novel

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

coronavirus - Africa_Zambia-focused subsampling [Internet]. [cited 2022 Feb 16]. Available from: https://nextstrain.org/groups/SC2ZamPub/ncov/africa/zambia

21. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob Heal. 2021;(21):1–9.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Table 1. Characteristics and outcomes of cases and controls during an COVID-19 outbreak in a prison in Zambia, December 2021

Variable	Cases* (N=180)	Controls* (N=202)	p-value†
Age, median years (IQR)	27 (21-36)	28 (21-36)	0.58
Imprisonment duration, median days (IQR)	41 (13-96)	43 (17-120)	0.79
Education level, n (%)			
None	5 (2.8)	5 (2.5)	0.34
Primary	68 (37.8)	63 (31.2)	
Secondary	82 (45.6)	111 (55)	
Tertiary	25 (13.9)	23 (11.4)	
Nationality, n (%)			
Zambian	143 (79.4)	176 (87.1)	0.06
Other	37 (20.6)	26 (12.9)	
Any comorbidity, n (%)‡	38 (21.1)	46 (22.8)	0.79
Comorbidity type, n (%)			
HIV	22 (12.2)	18 (8.9)	0.38
Hypertension	9 (5.0)	5 (2.5)	0.30
Cardiac disease	2 (1.1)	4 (2.0)	0.79
Diabetes	1 (0.6)	5 (2.5)	1.00
Renal disease	2 (1.1)	2 (1.0)	0.92
Pulmonary disease	1 (0.6)	1 (0.5)	1.00
Tuberculosis	1 (0.6)	2 (1.0)	1.00
Liver disease	1 (0.6)	1 (0.5)	1.00
Other	6 (3.4)	14 (7.1)	0.18
Prior COVID-19, n (%)	5 (2.8)	11 (5.4)	0.13
Mask use			
Always or most of the time	97 (53.9)	106 (52.5)	0.14
Sometimes or rarely	51 (28.3)	72 (35.6)	
Don't use a mask	32 (17.8)	24 (11.9)	
Timing of 1st Vaccine Dose, n (%)			
≥14 days before testing	118 (65.0)	168 (83.2)	<0.01
0-13 days before testing¶	4 (2.2)	4 (2.0)	
After testing	0 (0.0)	0 (0.0)	
Not vaccinated	58 (32.2)	30 (14.9)	
Vaccine type (n = 294), n (%)			
Janssen (J&J)	110 (90.2)	151 (87.8)	0.75
AstraZeneca	11 (9.0)	20 (11.6)	
Not known	1 (0.8)	1 (0.6)	
Vaccination status, n (%)**			
Fully	117 (65.0)	166 (82.2)	<0.01
Partially	0 (0.0)	1 (0.5)	
Indeterminate	5 (2.8)	5 (2.5)	
Unvaccinated	58 (32.2)	30 (14.9)	

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Time since vaccination, median days (IQR)	56 (33-91)	53 (27-84)	0.02
Symptomatic, n (%)	82 (45.6)	22 (10.9)	<0.01
Symptoms, n (%)			
Cough	68 (37.8)	18 (8.9)	1.00
Rhinorrhea	37 (20.6)	6 (3.0)	0.21
Headache	31 (20.6)	6 (3.0)	0.51
Myalgia	23 (12.8)	2 (1.0)	0.12
Fever	18 (10.0)	3 (1.5)	0.57
Fatigue	10 (5.6)	1 (0.5)	0.52
Sore throat	9 (5.0)	6 (3.0)	1.00
Chills	6 (3.3)	2 (1.0)	1.00
Sinus congestion	3 (1.7)	1 (0.5)	NC
Loss of taste	2 (1.1)	0 (0.0)	NC
Loss of smell	2 (1.1)	0 (0.0)	NC
Others	5 (2.8)	2 (1.0)	NC
Sought health care, n (%)	89 (49.4)	17 (8.4)	<0.01
Admitted to hospital, n (%)	0 (0.0)	0 (0.0)	NC
Died, n (%)	0 (0.0)	0 (0.0)	NC

* Cases were participants with a positive SARS-CoV-2 rapid diagnostic test (RDT) results and controls were participants with a negative RDT result

[†] Student's t-test for continuous variables and chi-square test or Fischer exact test (where any cell size <10) for categorical variables

[‡] Comorbidities included: hypertension, cardiac disease, obesity, pulmonary disease, kidney disease, liver disease, diabetes, cancer, HIV, and tuberculosis (current or past)

[¶] Participants classified as indeterminate because immune status at time of testing was unknown

** Partial vaccination was defined has having received the 1st dose of a two-dose vaccine ≥14 days before COVID-19 testing but not the second dose or the 2nd dose ≤13 days before testing. Full vaccination was defined having received the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days before COVID-19 testing. Persons who were vaccinated with their 1st dose 0-13 days before testing were considered to have indeterminate vaccination status and excluded from analyses.

IQR: interquartile range; NC: not calculated

290 Table 2. COVID-19 vaccine effectiveness against Omicron variant – Zambia, December 2021

Vaccination status	Fully vaccinated, n (%)		Vaccine effectiveness, % (95% CI)*	
	Cases	Controls	SARS-CoV-2 infection	Symptomatic infection
Vaccine brand†				
Any vaccine (n = 371)	117 (66.9)	166 (84.7)	64.8 (36.1-81.0)	72.9 (42.0-87.5)
Janssen (n = 341)	106 (64.6)	147 (83.1)	63.6 (33.6-80.5)	73.0 (41.6-87.7)
AstraZeneca (n = 118)	11 (15.9)	19 (38.8)	89.4 (59.5-97.8)	85.1 (19.5-98.0)
Vaccination timing†				
≤60 days (n = 249)	59 (50.4)	102 (77.3)	74.6 (50.3-87.4)	83.7 (60.8-93.6)
>60 days (n = 210)	58 (50.0)	64 (68.1)	54.2 (6.9-77.9)	53.2 (-16.6-81.6)

* Adjusted for age, number of comorbidities, jail cell, and mask use
† Analysis presented for fully vaccinated persons only. One person was partially vaccinated and 10 were indeterminate vaccination status (i.e., vaccinated with their 1st dose 0-13 days before COVID-19 testing)
CI: confidence interval

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.06.22274701; this version posted May 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

291